top of page
Enabling Bedside Manufacturing of Viral Vaccines and Cell & Gene Therapies

Currently, there is a serious lack of supply of virus particles for gene therapies and for vaccines in case of a pandemic emergency (influenza, coronavirus disease). Manufacturing capacity is limited to a handful of facilities relying on complicated, slow, and inefficient processes designed for specific products.


Expanding manufacturing capacity with traditional technologies will not improve the current situation:

It is estimated that a tenfold improvement in virus manufacturing is needed to enable the growth of the gene therapy market ($11 bn by 2025).

ContiVir is developing highly efficient virus production technologies than can be used for a wide range of virus-based products (around half of the current coronavirus vaccine candidates) and that have the potential to resolve the issues above by simplifying, miniaturizing, and de-centralizing manufacturing.

Learn more about Our Technologies.

Read user Testimonials.

bottom of page